InvestorsHub Logo
Followers 0
Posts 857
Boards Moderated 0
Alias Born 08/28/2009

Re: None

Wednesday, 05/04/2011 2:37:20 AM

Wednesday, May 04, 2011 2:37:20 AM

Post# of 129054
IMO, GW has the funding to get Sativex FDA approved this year.

'The Phase III cancer pain programme is being performed in conjunction with GW's licensing partner for Sativex® in the US, Otsuka Pharmaceutical Co. Ltd. The programme, which is fully funded by Otsuka, includes two Phase III randomised placebo-controlled multi-centre multinational trials as well as a long term extension study. Each Phase III trial will include approximately 370 patients and will evaluate the efficacy and safety of Sativex® versus placebo over a 5 week treatment period."

We know this is going to happen and when it does the ingredients are going to be rescheduled and FDA approved. After all,this alliance is now 4 years in the making.

I'm counting on Dr. Bob to get a patent, delivery methods (like SFIO), and their own FDA approval. But that is in the near future.

Right now, it makes sense to amass documented clinical records. Riding on the coat tails of Otsuka and other has its advantages, especially when you know you have winning strains that can be blended to a standardized product.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.